Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 50,000 shares at $64.63 ($3.4M) on 2026-05-11, disclosed to the SEC on 2026-05-13.
Scheduled sale ($3.4M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.63 | 9,725 | $629K | 18.3% |
| 2 | $65.46 | 3,575 | $234K | 6.8% |
| 3 | $66.33 | 6,700 | $444K | 12.9% |
| 4 | $67.85 | 100 | $7K | 0.2% |
| 5 | $70.29 | 1,398 | $98K | 2.9% |
| 6 | $71.37 | 9,802 |
| $700K |
| 20.4% |
| 7 | $72.15 | 5,900 | $426K | 12.4% |
| 8 | $73.12 | 2,800 | $205K | 6.0% |
| 9 | $68.10 | 2,100 | $143K | 4.2% |
| 10 | $68.88 | 3,350 | $231K | 6.7% |
| 11 | $69.79 | 3,950 | $276K | 8.0% |
| 12 | $70.81 | 600 | $42K | 1.2% |
| Total | $68.68 avg | 50,000 | $3.4M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-04-07 | $635K | — | Filing → |